738 related articles for article (PubMed ID: 32281330)
1. [Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].
Wang H; Jin XY; Pang B; Liu CX; Zheng WK; Yang FW; Pang WT; Zhang JH
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1232-1241. PubMed ID: 32281330
[TBL] [Abstract][Full Text] [Related]
2. [Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules].
Yan BH; Jiang ZW; Zeng JP; Tang JY; Ding H; Xia JL; Qin SR; Jin SC; Lu Y; Zhang N; Wang ZH; Li HY; Sang XY; Wu LN; Tang SY; Li Y; Tao MY; Wang QL; Wang JD; Xie HY; Chen QY; Yang SW; Hu NS; Yang JQ; Bao XX; Zhang Q; Yang XL; Jiang CY; Luo HY; Cai ZH; Yu SG
Zhongguo Zhong Yao Za Zhi; 2020 Jul; 45(13):2993-3000. PubMed ID: 32726003
[TBL] [Abstract][Full Text] [Related]
3. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial.
Xiao M; Tian J; Zhou Y; Xu X; Min X; Lv Y; Peng M; Zhang Y; Yan D; Lang S; Zhang Q; Fan A; Ke J; Li X; Liu B; Jiang M; Liu Q; Zhu J; Yang L; Zhu Z; Zeng K; Li C; Zheng Y; Wu H; Lin J; Lian F; Li X; Tong X
Pharmacol Res; 2020 Nov; 161():105126. PubMed ID: 32781283
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.
Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G
Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
7. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis.
Zhang X; Cao D; Liu J; Zhang Q; Liu M
Medicine (Baltimore); 2020 Jul; 99(30):e21404. PubMed ID: 32791754
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of registered clinical trials on traditional Chinese medicine for coronavirus disease 2019 (COVID-19): A scoping review.
Luo H; Yang M; Tang QL; Hu XY; Willcox ML; Liu JP
Eur J Integr Med; 2021 Jan; 41():101251. PubMed ID: 33204368
[TBL] [Abstract][Full Text] [Related]
11. [Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway].
Ren Y; Yao MC; Huo XQ; Gu Y; Zhu WX; Qiao YJ; Zhang YL
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1225-1231. PubMed ID: 32281329
[TBL] [Abstract][Full Text] [Related]
12. Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019(COVID-19): Meta-analysis of randomized controlled trials.
Zeng M; Li L; Wu Z
PLoS One; 2020; 15(9):e0238828. PubMed ID: 32915877
[TBL] [Abstract][Full Text] [Related]
13. Clinical practice guidelines and experts' consensuses of traditional Chinese herbal medicine for novel coronavirus (COVID-19): protocol of a systematic review.
Li Y; Li J; Zhong D; Zhang Y; Zhang Y; Guo Y; Clarke M; Jin R
Syst Rev; 2020 Aug; 9(1):170. PubMed ID: 32746913
[TBL] [Abstract][Full Text] [Related]
14. Traditional Chinese Medicine as the Preventive and Therapeutic Remedy for COVID-19.
Gasmi A; Tippairote T; Mujawdiya PK; Menzel A; Lysiuk R; Shanaida M; Lenchyk L; Peana M; Bjørklund G
Curr Med Chem; 2024; 31(21):3118-3131. PubMed ID: 36999715
[TBL] [Abstract][Full Text] [Related]
15. Reduning injection combined with western medicine for pneumonia: A protocol for systematic review and meta-analysis.
Cao C; Zhen Z; Kuang S; Xu T
Medicine (Baltimore); 2020 Oct; 99(43):e22757. PubMed ID: 33120780
[TBL] [Abstract][Full Text] [Related]
16. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of Lianhua Qingwen (LHQW) for coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis.
Zhang Q; Cao F; Ji G; Xu X; Sun Y; Li J; Qi X; Sun S; Wang Y; Song B
Medicine (Baltimore); 2020 Jul; 99(30):e20979. PubMed ID: 32791675
[TBL] [Abstract][Full Text] [Related]
18. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
19. [Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus].
Zhang YS; Cong WH; Zhang JJ; Guo FF; Li HM
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1263-1271. PubMed ID: 32281335
[TBL] [Abstract][Full Text] [Related]
20. Traditional Chinese medicine to treat COVID-19: the importance of evidence-based research.
Wang J; Qi F
Drug Discov Ther; 2020; 14(3):149-150. PubMed ID: 32669523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
